ClinicalTrials.gg
CompletedNCT02253875Updated Oct 1, 2014

Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers

A Phase 1 interventional study of Tipranavir (TPV) and Ritonavir in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-01.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Study to determine the effects of multiple-dose omeprazole on the single-dose pharmacokinetics of tipranavir and ritonavir

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female healthy volunteers between 18 and 60 years of age inclusive
  2. Clinically normal medical history
  3. Clinically normal findings on physical examination
  4. Clinically normal laboratory values
  5. (BMI) between 18.5 and 30 kg/m2 inclusive
  6. Ability to swallow large capsules without difficulty
  7. Capable of comprehending and communicating effectively with the investigator and site staff
  8. Signed and dated written form, in accordance with Ethics Committee and regulatory guidelines prior to trial participation
  9. Willingness to abstain from ingesting substances which may alter plasma drug levels by interactions with the cytochrome P450 system during the 14 days of the study
  10. Willingness to abstain from alcohol for 48 hours prior to Visit 2 and for the duration of the study
  11. Willingness to abstain from ingesting grapefruit and grapefruit juice for 7 days before Visit 2 and for the duration of the study
  12. Negative pregnancy test (β-hCG)
  13. Negative serology
  14. Negative hepatitis serology

Exclusion criteria

Exclusion Criteria:

  1. Any disease (a significant disease is defined as a disease, which in the opinion of the investigator may either put the subject at risk because of participation in the study, or a disease which may influence the results of the study or the subject's ability to participate in the study)
  2. Clinically significant abnormal baseline hematology, blood chemistry or urinalysis findings normal at Visit 2
  3. Serum (ALT), Aspartate Aminotransferase (AST), cholesterol, triglyceride or glucose greater than the at Visit 2
  4. Treatment with any drug within 90 days prior to the first dose of study medication
  5. Inability to adhere to the requirements of the protocol as assessed by the investigator
  6. Prior TPV use
  7. Subjects who are taking or have taken medications metabolized through the Cytochrome P-450 (CYP450) enzyme system within 30 days prior to Visit 2
  8. Subject with a seated systolic blood pressure either \<100 mmHg or >150 mmHg; resting heart rate either \<50 beats/min or >100 beats/min
  9. Subject with a history of any illness or allergy that in the investigator opinion might confound the results of the study, or pose additional risk to the subject with the administering of TPV/r or omeprazole
  10. Subject who have had an acute illness within 14 days prior to Visit 2
  11. Subject who are currently taking or have taken over-the-counter medications in the 14 days prior to Visit 2, or subjects who are currently taking any prescription medication
  12. Known to TPV, RTV, omeprazole or antiretroviral drugs (marketed or experimental use as part of clinical research studies)
  13. Female subjects who are of and who are:

    • Pregnant or breast-feeding
    • Have a positive serum β-hCG (pregnancy test) at screening visit (Visit 1)
    • Have not been using a barrier method for at least 60 days prior to Study Day 1
    • Are not willing to use a reliable method of double-barrier contraception during the trial and for 30 days after completion or termination of the trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    TPV + RTV + Omeprazole

    Drug: Tipranavir (TPV) · Drug: Ritonavir · Drug: Omeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum plasma concentration of Tipranavir in plasma)

    Time frame: up to 72 hours after drug administration

  2. AUC0-72h (Area Under Plasma Concentration-time curve of Tipranavir from 0-72 hr)

    Time frame: up to 72 hours after drug administration

Secondary outcomes

  1. Cmax (Maximum plasma concentration of Ritonavir in plasma)

    Time frame: up to 72 hours after drug administration

  2. AUC0-72h (Area Under Plasma Concentration-time curve of Ritonavir from 0-72 hr)

    Time frame: up to 72 hours after drug administration

  3. AUC0-∞ (Area Under Plasma Concentration-time curve from 0 to infinity)

    Time frame: up to 72 hours after drug administration

  4. MRT (Mean residence time)

    Time frame: up to 72 hours after drug administration

  5. t1/2 (apparent terminal halflife)

    Time frame: up to 72 hours after drug administration

  6. Tmax (Time to maximum concentration of the analyte in plasma)

    Time frame: up to 72 hours after drug administration

  7. CL/F (Oral clearance)

    Time frame: up to 72 hours after drug administration

  8. Vz/F (Apparent volume of distribution during the terminal elimination phase divided by the bioavailability factor)

    Time frame: up to 72 hours after drug administration

  9. Number of subjects with adverse events

    Time frame: up to 24 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005 and a primary completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2014
First posted
Oct 1, 2014
Start
Nov 2005
Primary completionActual
Feb 2006
Last update
Oct 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02253875
Responsible party
Sponsor
First posted
Oct 1, 2014
Start date
Nov 2005
Primary completion
Feb 2006
Last update
Oct 1, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Ritonavir · Omeprazole

Start the discussion